Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 1Prostatic Neoplasms 1Lymphoma, Follicular 1

Interventions

Rituximab 53Cyclophosphamide 50Lenalidomide 41fludarabine 24obinutuzumab 23Prednisone 19Bendamustine Hydrochloride 19Magnetic Resonance Spectroscopy 18Vincristine 17Doxorubicin 16fludarabine phosphate 15Specimen Handling 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tafasitamab 4polatuzumab vedotin 4acalabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × deucravacitinib × 1 year × Clear all
NCT07256015 2025-12-01

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Bristol-Myers Squibb

Recruiting
200 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡